Not provided
Not provided
Not provided
Not provided
Not provided
Poor recruitment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Mitacs | INDUSTRY |
| Medtronic - MITG | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Major surgery results in a stress- induced catabolic response, marked by post-operative insulin resistance, hyperglycemia and loss of body protein, which is associated with increased morbidity, mortality and adverse outcomes. There has been a great deal of research on different approaches to optimize post-operative insulin sensitivity including hormonal and nutritional interventions, minimally invasive surgical techniques and epidural anesthesia. However, the correlation between insulin resistance and body protein loss is not well understood. Metformin is the most widely used insulin sensitizing and blood glucose-lowering drug in treatment of type 2 diabetic patients. This study will: 1) estimate the correlation between insulin resistance and body protein loss in pre-diabetic lung/colorectal resection patients; 2) investigate whether the post-operative metabolic state can be improved by the pre-operative administration of metformin; and assess the impact of metformin on surgical complications and hospital length of stay. The results of this study will provide insight into the relationship between insulin resistance and post-operative adverse events and potentially suggest a novel approach to improve outcomes using Metformin, a drug already in wide clinical use.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Metformin | Active Comparator | Metformin will be administered as pills to be taken orally with an initial dose of 850 mg on the first day; the dose will be increased to 850 mg every 12 hours and 850mg every 8 hours respectively on the second day and then on the days to follow up to the morning of the surgery. Metformin will be discontinued on the day of surgery and will be restarted immediately after surgery. |
|
| Placebo | Placebo Comparator | Placebo will be administered exactly in the similar way to Metformin |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Metformin | Drug | Patients will take metformin for two weeks before Surgery and 2 days after the surgery |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in fasting blood glucose | the level of plasma glucose after 6 hours of fasting | 2 weeks before surgery (pre-operative) and on the morning before the surgery and every morning after the surgery (post operative) for three days or until discharge which ever comes earlier |
| Measure | Description | Time Frame |
|---|---|---|
| Change in whole body protein balance | The difference between the Pre-operative whole body protein balance( prior to metformin treatment) and the post operative whole body protein balance | 2 weeks before surgery (pre-operative) and hours after the surgery (post operative) |
| Comparing the Homeostasis model assessment (HOMA) index at three different time points ( by employing Fasting blood sugar and Plasma Insulin) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Liane Feldman, MD | McGill University Health Centre/Research Institute of the McGill University Health Centre | Principal Investigator |
| Francesco Carli, MD | McGill University Health Centre/Research Institute of the McGill University Health Centre | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Montreal General Hospital | Montreal | Quebec | H3G 1A4 | Canada |
Not provided
| ID | Term |
|---|---|
| D018149 | Glucose Intolerance |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D006943 | Hyperglycemia |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008687 | Metformin |
| ID | Term |
|---|---|
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery |
|
| at 3 time points as follow : 2 weeks before surgery, on the day of surgery and 48 hours after the surgery |
| glycosylated Hba1c | plasma level of glycosylated Hba1c | 2 weeks before surgery |
| Comparing the pre-operative body impedance and the post operative body impedance (to asses the body composition specifically the amount of body fat) | Measures body composition specifically fat content | 2 weeks before surgery and 48 hours after the surgery |
| Surgical Complications | Any complication related to the surgery with in 30 days post operation | 30 days after operation |
| length of hospital stay | Length of hospital stay is calculated as the total length of hospitalization from the date of admission for the purpose of surgery until the date of discharge from the hospital | Up to 30 days after operation |
| D006946 | Hyperinsulinism |